Two years after Congress passed the 21st Century Cures Act, US FDA has finalized a guidance that lays out a pathway that fast-tracks certain high-priority medical devices by easing interactions with regulators. And in one major part of the guidance, the agency outlines conditions for “sprint” discussions to ensure sponsors get quick responses to important development questions.
As part of the 21st Century Cures Act, lawmakers required FDA to develop a new pathway called the Breakthrough Devices Program
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?